NBTX Nanobiotix S.A.

Nasdaq nanobiotix.com


$ 26.17 $ -0.47 (-1.78 %)    

Friday, 17-Oct-2025 12:02:23 EDT
QQQ $ 602.53 $ 4.95 (0.83 %)
DIA $ 461.25 $ 1.89 (0.41 %)
SPY $ 662.71 $ 3.24 (0.49 %)
TLT $ 91.11 $ -0.12 (-0.13 %)
GLD $ 387.83 $ -9.37 (-2.36 %)
$ 26.57
$ 26.43
$ 25.61 x 100
$ 27.06 x 100
$ 25.89 - $ 26.83
$ 2.76 - $ 30.35
53,899
na
1.26B
$ 0.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nanobiotix-announces-first-data-from-cohorts-1-and-2-of-dose-escalation-part-of-phase-1-study-evaluating-jnj-1900-for-eadc-patients

Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the...

 nanobiotix-h1-eps-012-up-from-050-yoy-sales-30202m-up-from-10001m-yoy

Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.12) per share. This is a 76 percent increase over losses of $(0.50) p...

 nanobiotix-jj-therapy-shows-promise-in-tough-head-and-neck-cancer

Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and surviva...

 reported-earlier-nanobiotix-reports-updated-phase-1-data-showing-jnj-1900-nbtxr3-plus-anti-pd-1-achieves-37-orr-and-63-dcr-in-nave-rm-hnscc-patients

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïv...

 stitch-fix-posts-q4-results-joins-transocean-mbx-biosciences-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc....

 why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

 melanoma-data-study-boosts-jj-partner-nanobiotix-stock-on-thursday

Nanobiotix reported melanoma study data showing JNJ-1900 delivered 47.4% response rate, 78.9% disease control, and 14.6 months ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION